Thomas White, MD
Interventional Pain Medicine · Shenandoah, TXNPI 1396181350
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,128 of the $118,436 with a category attached, or 63.4%. Medtronic accounts for 68.9% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2024 at $52,089 and has fallen 93.4% since, to $3,445 in 2025. Among interventional pain medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 611 payments — averaging $193.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$82K
- Nevro Corp.$26K
- Abbott$4K
- Vertiflex, Inc.$1K
- Globus Medical$1K
- Boston Scientific$1K
- plus $4K from 44 others
Across 34 payments — averaging $1916.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$45K
- Nevro Corp.$13K
- Globus Medical$7K
What the payments were for
- Consulting fees$15,89313%
- Speaking & faculty fees$75,12863%
- Travel & lodging$9,9418%
- Food & beverage$17,47515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$69,004
- Vyrsa V1$24,200
- SYNCHROMEDII$2,832
- VANTA ADAPTIVESTIM$2,293
- Senza$1,914
- PROCLAIM$1,829
- Superion ISS$1,224
- INTELLIS$997
- SPECIFY SURESCAN MRI 5-6-5$820
- Intracept$279
- KYPHON EXPRESS II KYPHOPAK TRAY$161
- ETERNA$155
- VECTRIS$150
- Minuteman$133
- V-LOC 180$118
- SUPERION$111
- RESTORE$111
- Axium$111
- Qutenza$106
How this compares
$118,436 in reported general payments places this provider in the 95th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,815 | $56,899 |
| UbrelvyUbrogepant | 24 | $40,243 |
| RelistorMethylnaltrexone Bromide | 16 | $38,015 |
| Buprenorphine | 107 | $29,493 |
| BelbucaBuprenorphine Hcl | 29 | $22,247 |
| Pregabalin | 1,056 | $17,846 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 467 | $16,447 |
| Lidocaine | 173 | $14,186 |
| MaxaltRizatriptan Benzoate | 11 | $14,100 |
| MovantikNaloxegol Oxalate | 32 | $13,947 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 64 | $11,153 |
| Tizanidine Hcl | 554 | $6,634 |
| Gabapentin | 499 | $6,472 |
| Cyclobenzaprine Hcl | 697 | $5,831 |
| Diclofenac Sodium | 164 | $5,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $746 | $40,24324 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $65 | $38,01516 claims |
| Redhill Biopharma Inc.Movantik | $18 | $13,94732 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $149 | $4,50913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Shenandoah
- Ankur KhoslaShenandoah$277K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
- Alan SilberbergKyle$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.